Ipca Laboratories' Q4 FY 2025-26 Quarterly Results

Result Summary

• Ipca Laboratories Ltd reported a 2.9% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 9.2%.
• Its expenses for the quarter were up by 2.4% QoQ and 4.8% YoY.
• The net profit decreased 15.7% QoQ and increased 379.3% YoY.
• The earnings per share (EPS) of Ipca Laboratories Ltd stood at 11.79 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Ipca Laboratories Ltd is a pharmaceutical company engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs). The company operates in the healthcare industry, focusing on producing a range of medicines including anti-infectives, anti-diabetics, anti-malarials, and cardiovascular products. As of October 2023, Ipca Laboratories has been recognized for its robust product pipeline and its significant role in the pharmaceutical manufacturing sector. However, specific recent major developments within the company are not available based on the data provided.

Revenue

For the fourth quarter of fiscal year 2026 (Q4FY26), Ipca Laboratories Ltd reported a total income of ₹2482.22 crores. This represents a quarter-over-quarter (QoQ) increase of 2.9% from the previous quarter (Q3FY26), where the total income was ₹2412.69 crores. On a year-over-year (YoY) basis, the company experienced a 9.2% increase compared to the fourth quarter of fiscal year 2025 (Q4FY25), when the total income was ₹2272.51 crores. This upward trend in revenue suggests a steady growth in the company's income generation capabilities over the year.

Profitability

In Q4FY26, Ipca Laboratories Ltd recorded a profit before tax of ₹404.45 crores, reflecting a decrease of 9.3% from Q3FY26, which was ₹445.98 crores. However, when compared to Q4FY25, where the profit before tax was ₹128.00 crores, there is a significant YoY increase of 216.0%. The tax expense for Q4FY26 was ₹95.05 crores, up by 16.0% from Q3FY26 and 52.8% from Q4FY25. The profit after tax for Q4FY26 was ₹306.69 crores, a QoQ decline of 15.7% from ₹363.67 crores in Q3FY26, but a substantial YoY increase of 379.3% compared to ₹63.99 crores in Q4FY25. The earnings per share (EPS) for Q4FY26 were ₹11.79, which shows a QoQ decrease of 8.3% from ₹12.86 in Q3FY26, but a significant YoY increase of 341.6% from ₹2.67 in Q4FY25.

Operating Metrics

The total expenses for Ipca Laboratories Ltd in Q4FY26 were ₹2031.95 crores, marking a 2.4% QoQ increase from ₹1984.36 crores in Q3FY26 and a 4.8% YoY increase from ₹1939.46 crores in Q4FY25. These figures highlight the company's operational expenditure trends over the quarters. The consistent increase in total expenses suggests a scaling in operations, which is also reflected in the increase in total income. Furthermore, the substantial YoY growth in profitability metrics indicates a notable improvement in the company's financial performance compared to the previous year.